A5018735767- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Meningioma and schwannoma management
- Radiomics and Machine Learning in Medical Imaging
- Neuroblastoma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- Advanced Radiotherapy Techniques
- Cancer-related cognitive impairment studies
- Management of metastatic bone disease
- Lung Cancer Treatments and Mutations
- Ocular Oncology and Treatments
- Neurofibromatosis and Schwannoma Cases
- Pituitary Gland Disorders and Treatments
- Nanoplatforms for cancer theranostics
- Chromatin Remodeling and Cancer
- Medical Imaging Techniques and Applications
- Breast Cancer Treatment Studies
- Epigenetics and DNA Methylation
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Renal cell carcinoma treatment
- MRI in cancer diagnosis
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
University Hospital Leipzig
2016-2025
Leipzig University
2016-2025
Comprehensive Cancer Center Mainfranken
2024
Heidelberg University
2011-2023
University Hospital Heidelberg
2011-2023
Klinik und Poliklinik für Strahlentherapie und Radioonkologie
2016-2023
University Cancer Center Hamburg
2018
National Center for Tumor Diseases
2012
German Cancer Research Center
2012
University of Tübingen
2011
Abstract Background Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy depatuxizumab mafodotin (depatux-m), an antibody–drug conjugate comprised a monoclonal antibody that binds activated EGFR (overexpressed wild-type EGFRvIII-mutant) linked to microtubule-inhibitor toxin in EGFR-amp GBMs. Methods In this phase III trial, adults with centrally confirmed,...
Abstract Purpose: To investigate whether TP53 mutation, 1p/19q codeletions, O6-methylguanylmethyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutation predict natural course of disease or response to radiotherapy chemotherapy both in low-grade glioma patients. Experimental Design: Cohort A consisted 89 patients with diffuse astrocytoma World Health Organization (WHO) grade II (n = 40), oligoastrocytoma 23), oligodendroglioma 26) who did not receive after...
Abstract The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy (RT) by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part GLORIA (NCT04121455), a phase I/II trial combining RT and CXCL12-neutralizing aptamer olaptesed pegol (NOX-A12; 200/400/600 mg per week) in patients with incompletely resected, newly-diagnosed GBM lacking MGMT methylation. primary endpoint was safety, secondary endpoints included maximum tolerable dose (MTD),...
Abstract Background Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as central biological hub in tumor cells. Marizomib is novel pan-proteasome inhibitor that crosses the blood–brain barrier. Methods European Organisation Research Treatment Cancer 1709/Canadian Trials Group CE.8 was multicenter,...
Medulloblastoma in adult patients is rare, with 0.6 cases per million. Prognosis depends on clinical factors and medulloblastoma entity. No prospective data the feasibility of radiochemotherapy exist. The German Neuro-Oncology Working Group (NOA) performed a descriptive multicenter single-arm phase II trial to evaluate toxicity radio-polychemotherapy.The NOA-07 combined craniospinal irradiation vincristine, followed by 8 cycles cisplatin, lomustine, vincristine. Adverse events, imaging...
Therapeutic options for patients with brain metastases (BM) increase. While these lead to considerable survival effects in subgroups, there is limited knowledge about characteristics, prognosticators and treatment BM short survival. Patients a time of ≤ 6 months (short-term survivors, STS), diagnosed between 2009-2021 at large tertiary cancer center were analysed. Clinical pathological data causes death documented. Descriptive statistics, treatment-specific univariate Kaplan-Meier estimator...
The discovery of cellular tumor networks in glioblastoma, with routes malignant communication extending far beyond the detectable margins, has highlighted potential supramarginal resection strategies. Retrospective data suggest that these approaches may improve long-term disease control. However, their application is limited by proximity critical brain regions and vasculature, posing challenges for validation randomized trials. Anterior temporal lobectomy (ATL) a standardized surgical...
Abstract Background and purpose Bone metastases constitute a common indication for both conventional radiotherapy (RT) stereotactic body (SBRT). Although in recent years guidelines have been proposed SBRT of spinal non-spinal metastases, little is known about the use bone actual patterns care German-speaking countries. Material methods We performed an online survey among radiation oncologists (ROs) registered with interdisciplinary Radiosurgery Stereotactic Radiotherapy Working Group German...
Abstract Purposes First, to evaluate outcome, the benefit of concurrent chemotherapy and prognostic factors in a cohort sixty-four high-grade glioma patients who underwent second course radiation therapy at progression. Second, validate new score for overall survival after reirradiation progressive gliomas with an independent patient cohort. Patients methods All fractionated median physical dose 36 Gy. Median planned target volume was 110.4 ml. Thirty-six received consisting 24/36 cases...
2004 Background: Patients with newly diagnosed glioblastoma receive postoperative standard therapy radiotherapy (RT), and concomitant up to six cycles of maintenance temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). Marizomib is a novel, irreversible brain-penetrant pan-proteasome inhibitor encouraging findings in preclinical models early-stage clinical trials for patients recurrent glioblastoma. Therefore, phase 3 trial was designed explore the activity marizomib addition TMZ/RT→TMZ....
Glioblastoma is the most frequent and malignant primary brain tumor. Even in subgroup with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation favorable response to first-line therapy, survival after relapse short (12 months). Standard therapy for recurrent MGMT-methylated glioblastoma not standardized may consist of re-resection, re-irradiation, chemotherapy temozolomide (TMZ), lomustine (CCNU), or a combination thereof. Preclinical results show that meclofenamate (MFA),...
Abstract Detection of tumor progression in patients with glioblastoma remains a major challenge. Extracellular vesicles (EVs) are potential biomarkers and can be detected the blood glioblastoma. In our study, we evaluated serum‐derived EVs from to serve as biomarker for progression. serum healthy volunteers were separated by size exclusion chromatography ultracentrifugation. EV markers defined using proximity‐extension assay bead‐based flow cytometry. Tumor was according modified RANO...
Multimodal therapies have significantly improved prognosis in glioma. However, particular radiotherapy may induce long-term neurotoxicity compromising patients' neurocognition and quality of life. The present prospective multicenter study aimed to evaluate associations multimodal treatment with a focus on hippocampal irradiation.Seventy-one glioma patients (WHO grade 1-4) were serially evaluated neurocognitive testing life questionnaires. Prior (baseline) following further (median 7.1 years...
Abstract Background Peritumoral edema is a characteristic feature of malignant glioma related to the extent neovascularisation and vascular endothelial growth factor (VEGF) expression. The peritumoral VEGF expression may be prognostic for patients with glioblastoma. As older age negative marker as reported increased in primary glioblastoma patients, age-related differences have been assessed. Methods In retrospective, single-center study, preoperative magnetic resonance imaging (MRI) scans...